Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease

A.J. Aschenbrenner; R. Asaad Baksh; Bessy Benejam; J.A. Beresford-Webb; Antonia Coppus; Juan Fortea; Benjamin L Handen; S. Hartley; E. Head; J. Jaeger; J. Levin; S.V. Loosli; A.S. Rebillat; S. Sacco; F.A. Schmitt; K.E. Thurlow; Shahid Zaman; J. Hassenstab; A. Strydom

doi:10.1002/dad2.12184

Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease

A.J. Aschenbrenner, R. Asaad Baksh, Bessy Benejam, J.A. Beresford-Webb, Antonia Coppus, Juan Fortea, Benjamin L Handen, S. Hartley, E. Head, J. Jaeger, J. Levin, S.V. Loosli, A.S. Rebillat, S. Sacco, F.A. Schmitt, K.E. Thurlow, Shahid Zaman, J. Hassenstab, A. Strydom

Departament de Medicina

Munich Cluster for Systems Neurology (SyNergy)

Producció científica: Contribució a una revista › Article › Recerca › Avaluat per experts

13 Cites (Scopus)

Resum

Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting predementia stages. Methods: We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time.We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria. Results: There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted ofmemory, language/executive functioning, selective attention, orientation, and praxis tests. Discussion:We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.

Idioma original	English
Revista	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volum	13
Número	1
DOIs	https://doi.org/10.1002/dad2.12184
Estat de la publicació	Publicada - 2021

Accés al document

10.1002/dad2.12184

https://ddd.uab.cat/record/272154

Com citar-ho

Aschenbrenner, A. J., Asaad Baksh, R., Benejam, B., Beresford-Webb, J. A., Coppus, A., Fortea, J., Handen, B. L., Hartley, S., Head, E., Jaeger, J., Levin, J., Loosli, S. V., Rebillat, A. S., Sacco, S., Schmitt, F. A., Thurlow, K. E., Zaman, S., Hassenstab, J., & Strydom, A. (2021). Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 13(1). https://doi.org/10.1002/dad2.12184

@article{c3608c200d5b447dbe1207de08992429,

title = "Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease",

abstract = "Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting predementia stages. Methods: We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time.We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria. Results: There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted ofmemory, language/executive functioning, selective attention, orientation, and praxis tests. Discussion:We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.",

keywords = "Alzheimer's disease, Clinical trial outcome, Composite measure, Down syndrome, Early cognitive decline",

author = "A.J. Aschenbrenner and {Asaad Baksh}, R. and Bessy Benejam and J.A. Beresford-Webb and Antonia Coppus and Juan Fortea and Handen, {Benjamin L} and S. Hartley and E. Head and J. Jaeger and J. Levin and S.V. Loosli and A.S. Rebillat and S. Sacco and F.A. Schmitt and K.E. Thurlow and Shahid Zaman and J. Hassenstab and A. Strydom",

year = "2021",

doi = "10.1002/dad2.12184",

language = "English",

volume = "13",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "1",

}

Aschenbrenner, AJ, Asaad Baksh, R, Benejam, B, Beresford-Webb, JA, Coppus, A, Fortea, J, Handen, BL, Hartley, S, Head, E, Jaeger, J, Levin, J, Loosli, SV, Rebillat, AS, Sacco, S, Schmitt, FA, Thurlow, KE, Zaman, S, Hassenstab, J & Strydom, A 2021, 'Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 13, núm. 1. https://doi.org/10.1002/dad2.12184

Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease. / Aschenbrenner, A.J.; Asaad Baksh, R.; Benejam, Bessy et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1, 2021.

Producció científica: Contribució a una revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease

AU - Aschenbrenner, A.J.

AU - Asaad Baksh, R.

AU - Benejam, Bessy

AU - Beresford-Webb, J.A.

AU - Coppus, Antonia

AU - Fortea, Juan

AU - Handen, Benjamin L

AU - Hartley, S.

AU - Head, E.

AU - Jaeger, J.

AU - Levin, J.

AU - Loosli, S.V.

AU - Rebillat, A.S.

AU - Sacco, S.

AU - Schmitt, F.A.

AU - Thurlow, K.E.

AU - Zaman, Shahid

AU - Hassenstab, J.

AU - Strydom, A.

PY - 2021

Y1 - 2021

N2 - Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting predementia stages. Methods: We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time.We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria. Results: There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted ofmemory, language/executive functioning, selective attention, orientation, and praxis tests. Discussion:We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.

AB - Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting predementia stages. Methods: We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time.We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria. Results: There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted ofmemory, language/executive functioning, selective attention, orientation, and praxis tests. Discussion:We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.

KW - Alzheimer's disease

KW - Clinical trial outcome

KW - Composite measure

KW - Down syndrome

KW - Early cognitive decline

U2 - 10.1002/dad2.12184

DO - 10.1002/dad2.12184

M3 - Article

C2 - 33969175

SN - 2352-8729

VL - 13

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

ER -

Markers of early changes in cognition across cohorts of adults with down syndrome at risk of alzheimer's disease

Resum

Accés al document

Fingerprint

Com citar-ho